Alerta

METHOD FOR DIAGNOSING EARLY AND CLASSIFYING STAGES OF ALZHEIMER'S DISEASE AND DETERMINING AMYLOID BETA ACCUMULATION IN BRAIN BY USING TAU PROTEIN-DERIVED PHOSPHORYLATED PEPTIDE

Resumen de: US20260194539A1

A method for early diagnosis or stage classification of Alzheimer's disease includes obtaining a tau protein-derived phosphorylated peptide from an isolated biological sample and quantifying the tau protein-derived phosphorylated peptide. Through the quantification of tau protein-derived phosphorylated peptides, it is possible to effectively diagnose Alzheimer's disease at an early stage or classify its stages, and determine the accumulation of amyloid beta in the brain.

TARGETING GPR158 (MGLYR) WITH NANOBODIES FOR THERAPEUTIC BENEFITS

Resumen de: US20260193347A1

0000 The invention provides antibodies that specifically bind GPR158 and inhibit GAP activity of GPR158 via RGS7/Gβ5. The antibodies are useful in the diagnosis and treatment of affective disorders, mood disorders, and brain disorders.

BIOMARKERS PREDICTIVE OF IMMUNOMODULATORY MESENCHYMAL STROMAL CELLS

Resumen de: US20260194516A1

0000 The invention is based on a novel technology to identify inflammatory responsive elements (IREs) in a mesenchymal stromal cell (MSC) culture that allowed for the development of biomarkers, in particular CD55, CD146, CD271 and MSCA-1, or combinations thereof. The biomarkers of the invention are indicative for an immunomodulatory activity of an MSC. Consequently, the present invention pertains a first aspect, to a method for determining a presence or absence of an immunomodulatory activity of a mesenchymal stromal cell (MSC). Furthermore, in a second aspect, a method for the manufacture of an immunomodulatory preparation derived from an MSC with immunomodulatory activity is disclosed. In a third and fourth aspect, the invention pertains to an immunomodulatory preparation derived from an MSC with immunomodulatory activity and its medical use. In further aspects, the invention also pertains to methods for identifying an immunomodulatory population and an immunomodulatory subpopulation of MSCs with a known presence and/or expression of a biomarker respectively, and to an agent for determining a presence or absence of an immunomodulatory activity of an MSC.

Compositions and Methods of Treating Neurological Conditions

Resumen de: US20260191829A1

0000 Pharmaceutical compositions containing a dopamine Putamen reuptake inhibitor or a dopaminergic agonist, an adrenoceptor antagonist, and a pharmaceutically acceptable carrier, and methods for treating neurological diseases by administering the composition.

RATIONAL DESIGN STRATEGY FOR LOW-MOLECULAR-WEIGHT PROTEIN SECONDARY STRUCTURE MIMETICS AND MANUFACTURING METHOD THEREFOR

Resumen de: WO2026146787A1

The purpose of the present invention is to develop a design strategy focusing on central secondary structure motifs, such as α-helix, β-strand, and β-turn, which are important for PPI recognition, by using a common core skeleton, thereby providing a low-molecular-weight PPI modulator having a wide range of therapeutic potentials, and a versatile platform for targeting PPI.

ANTIBODY BASED REAGENTS THAT SPECIFICALLY RECOGNIZE NEURODEGENERATIVE DISEASE RELATED FORMS OF THE PROTEIN TDP-43

Resumen de: US20260194540A1

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.

SCFV ANTIBODY THAT SPECIFICALLY BINDS Aβ, AND USE THEREOF

Resumen de: WO2026144428A1

Provided are an scFv antibody that specifically binds Aβ, an isolated nucleic acid encoding the antibody, a vector comprising the nucleic acid, a cell comprising the isolated nucleic acid or the vector, a method for preparing the scFv antibody that specifically binds Aβ, and a use of the scFv antibody that specifically binds Aβ in the preparation of a medicament for treating Alzheimer's disease.

SHORT CHAIN FATTY ACID COMPOUNDS AND USES THEREOF

Resumen de: AU2024411321A1

The present disclosure describes methods comprising obtaining a level of a biomarker in a subject and based on the level of the biomarker in the subject, continuing a short chain fatty acid therapy. The disclosed methods can comprise administering a composition comprising at least one short chain fatty acid. The disclosed methods can be used to treat an inflammatory condition, a skin disorder, or an autoimmune disorder.

RATIOMETRIC FLUORESCENT SENSOR CONSTRUCTED BASED ON G PROTEIN-COUPLED RECEPTOR AND ITS CONSTRUCTION METHOD

Resumen de: US20260193314A1

A ratiometric fluorescent sensor constructed based on a G protein-coupled receptor and its construction method are provided. It is discovered that by introducing a mutation at the same amino acid site (the third amino acid of the N-terminal linker) on a GRAB sensor, the GRAB sensor can be endowed with excitation ratiometric properties. The sensor with excitation ratiometric properties have high pH sensitivity, are not limited by the sensor's own expression level or external hardware conditions, maintain high stability of fluorescence brightness, can minimize fluorescence interference caused by motion, can sensitively detect neurotransmitter release, and have the potential for in vivo quantitative detection of neurotransmitter concentration.

ANTI-UNC5C ANTIBODIES AND USES THEREOF

Resumen de: AU2024398768A1

Assays for detecting the level of soluble UNC5C in a biological fluid sample from a patient, and the use of such levels as markers of neurodegenerative disease presence and/or severity are described. Antibodies and fragments thereof capable of binding to UNC5C, and the use of such antibodies for detecting the level of soluble UNC5C in a biological fluid sample from a patient are also described, as well as methods for detecting the level of soluble UNC5C in a biological fluid sample from a patient using anti-UNC5C antibodies in a clinical context.

METHOD AND REAGENTS FOR THE DETECTION OF AN AUTOANTIBODY

Resumen de: WO2026146226A1

The present invention relates to means and methods relevant to assessing the risk of developing and/or aiding in the diagnosis of an inflammatory vascular condition and/or a multimorbidity comprising a neurological autoimmune disease and an inflammatory vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having a neurological autoimmune disease. The present invention also relates to assessing the risk of developing and/or aiding in the diagnosis of a neurological autoimmune disease and/or a multimorbidity comprising a neurological autoimmune disease and a vascular condition by detecting a human autoantibody to VGLUT, preferably VGLUT2, in a sample obtained from a patient preferably having or suspected of having an inflammatory vascular condition.

ANTIBODIES THAT BIND TO POST-TRANSLATIONALLY MODIFIED C9ORF72 ARGININE-RICH DIPEPTIDE REPEAT PROTEINS AND USES THEREOF

Resumen de: WO2026147818A1

Isolated monoclonal antibodies that bind to methylated dipeptide repeat proteins (DRPs), e.g., ADMe-GR and SDMe-GR, and related antibody-based compositions and molecules are disclosed. Also disclosed are diagnostic and therapeutic methods for using the antibodies.

PROTEOMICS OF FITNESS

Resumen de: US20260196299A1

0000 Methods, systems, and kits are provided for assessing cardiorespiratory fitness and predicting cardiometabolic risk.

VOLATILE ACTIVITY-BASED NANOSENSORS AND USES THEREOF

Resumen de: WO2026147852A1

In some aspects, the disclosure relates to compositions and method for detection, classification, and treatment of disease or other body status. The methods and compositions may be methods or compositions for identification of diseases in patients using a nanosensor having an enzyme cleavage site linked to a volatile 5 reporter via a dipeptide linker.

TOTAL EXOSOME DETECTION ON AUTOMATED ROUTINE IMMUNOASSAY ANALYZERS

Resumen de: WO2026145969A1

Exosome Detection on automated Routine Immunoassay Analyzers The present invention relates to a method for detecting exosomes in a sample comprising providing the exosomes in an aqueous solution; interacting the exosomes with at least one first interactor molecule, wherein the interaction yields a complex comprising both an exosome and the first interactor molecule; interacting the complex of the previous step with at least a second interactor molecule linked to a chemiluminescent dye; interacting the complex of the previous step with a substrate or a bead and thereby immobilizing it; performing a washing step; identifying the complex of the previous step by performing a chemiluminescent reaction, wherein the identification results in a chemiluminescent emission of photons; and detecting the emission of photons. Also envisaged is a corresponding kit for detecting exosomes in a sample.

デュアルトランスポーター及び使用方法

Resumen de: WO2024263558A1

Described are dual transporters and methods of making and using the dual transporters. The dual transporters bind to a blood brain barrier transport protein and a second protein that is expressed on the luminal surface of the blood brain barrier or is a brain retention protein. The dual transporters improve delivery to the central nervous system.

PEPTIDES FOR THE DETECTION OF AMYLOID FIBRIL AGGREGATES

Resumen de: WO2025046049A1

The present invention relates to molecules that are capable of binding to amyloid fibril aggregates. The invention further describes methods for detecting the presence of amyloid fibril aggregates in a sample or a subject. The invention even further describes methods for treating pathologies caused by amyloid fibril aggregates.

Dementia Diagnosis Method Using Multiple Biomarkers

Resumen de: KR20260106296A

본 발명은 다중 바이오마커를 이용한 치매 진단에 관한 것으로, 특히 동일한 질병인 치매에 대하여 베타 아밀로이드나 타우 등 다양한 바이오마커를 동시에 측정하여 치매를 진단하는 방법에 관한 것이다. 본 발명은 혈액, 뇌척수액 또는 기타 생체 샘플에서 다수의 바이오마커를 측정하여 치매의 존재를 보다 정확하게 진단할 수 있는 방법에 관련된다.

Degenerative Brain Disease Diagnostic System Using Artificial Intelligence Algorithm

Resumen de: KR20260106387A

본 발명은 퇴행성 뇌질환, 특히 알츠하이머병, 파킨슨병, 헌팅턴병 및 기타 신경퇴행성 질환의 진단 시스템에 관한 것이다. 구체적으로는 다중 바이오마커를 이용하여 퇴행성 뇌질환의 진단을 수행하며, 이를 인공지능 알고리즘을 통해 정확히 분석하여 보다 효과적이고 신속한 진단을 수행할 수 있는 시스템을 제공하는 기술에 관한 것이다.

p-Tau231特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用

Resumen de: CN122344252A

本申请公开了一种p‑Tau231特异性抗体及其在阿尔茨海默症辅助诊断试剂盒的应用，属于免疫分析技术领域。本申请抗体重链CDRH1‑CDRH3的氨基酸序列分别依次如SEQ ID NO：1‑SEQ ID NO：3所示，轻链CDRL1的氨基酸序列如SEQ ID NO：4所示，轻链CDRL2的氨基酸序列为QA，轻链CDRL3的氨基酸序列如SEQ ID NO：5所示。本申请还提供了靶向p‑Tau231的抗体、检测p‑Tau231的化学发光试剂盒。本申请抗体亲和力高、灵敏度高且生产周期明显缩短，更适合作为核心原料应用于体外诊断试剂领域，可用于阿尔茨海默症的辅助诊断。

识别ApoE的兔源单克隆抗体

Resumen de: CN122344254A

0001 本发明提供了一种识别ApoE的兔源单克隆抗体，属于生物工程和生物检测技术领域。该单克隆抗体记为HZK31，包括HZK31‑B0002、HZK31‑B0005、HZK31‑B0007、HZK31‑B0011。本发明制备的兔源单克隆抗体可以高效特异性地识别人源ApoE。相比于小鼠或大鼠，本发明的兔源单克隆抗体结构更简单，具有更高的亲和力，更易于人源化。

バスルーム環境におけるユーザ検出及び識別

Resumen de: WO2020172645A1

Provided is a system for detecting a user of a bathroom. The system comprises at least one sensor coupled to a bathroom use analysis device, where the sensor generates data that can be used to detect and/or identify the user. Also provided is a method of detecting a user of a bathroom. The method comprises analyzing data generated by the sensor in the above system to detect and/or identify the user.

Multi-Channel Multi-Cartridge High-Sensitivity Immunoassay System

Resumen de: KR20260105078A

본 발명은 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 하나의 질병에 대하여 다중 바이오마커를 이용하여 정밀하고 정확하게 현장에서 진단할 수 있는 다채널 멀티 카트리지 고감도 면역분석 시스템에 관한 것이다.

Peptide ligand coating tips

Resumen de: KR20260104904A

0001a 본 발명은 펩타이드 리간드 코팅 팁에 관한 것으로, 특히 광산화 증폭 면역 분석 기기에 사용되는 펩타이드 리간드를 안정적이고 효율적으로 코팅할 수 있는 팁을 제공하는 것이다.

2 2-channel high-sensitivity immunoassay automated instrument

Nº publicación: KR20260104836A 06/07/2026

Solicitante:

주식회사앱솔로지

Resumen de: KR20260104836A

0001a 본 발명은 2채널 고감도 면역분석 자동화 기기에 관한 것으로, 특히 광산화 증폭을 이용하여 소량의 혈액 샘플로 질병을 파악하되, 퇴행성 뇌질환과 심혈관 질환을 동시에 현장에서 진단할 수 있는 2채널 고감도 면역분석 자동화 기기에 관한 것이다.